Target

GPRC5D

G-protein coupled receptor family C group 5 member D

36open trials
44trials in total
29publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Trial
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
31 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis
1 Nov 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
Concurrent administration of BCMA and GPRC5D CAR T cells for advanced multiple myeloma.
22 Oct 2026· Blood· PUBMED
Publication
Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma.
7 Oct 2026· HemaSphere· PUBMED
Trial
A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma
1 Oct 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
Cutaneous Toxicities of Anti-GPRC5D Bispecific Antibodies for Multiple Myeloma: Retrospective Study.
16 Sept 2026· The Journal of dermatology· PUBMED
Publication
Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.
8 Sept 2026· Blood advances· PUBMED
Publication
Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.
3 Sept 2026· Blood· PUBMED
Publication
A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in multiple myeloma.
3 Sept 2026· Blood cancer journal· PUBMED
Publication
BCMA versus GPRC5D bispecific antibodies in relapsed/refractory multiple myeloma: A systematic review and meta-analysis guiding treatment selection.
2 Sept 2026· British journal of haematology· PUBMED
Publication
GPRC5D-targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies.
1 Sept 2026· Cancer· PUBMED
Publication
Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience.
1 Sept 2026· Hematology (Amsterdam, Netherlands)· PUBMED
Publication
Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.
13 Aug 2026· Blood· PUBMED
Publication
T-Cell Engagers Targeting BCMA, GPRC5D, or FcRH5 in Relapsed/Refractory Multiple Myeloma: The Landscape Beyond CAR-T Cell Therapy-A Systematic Review and Network Meta-Analysis.
11 Aug 2026· International journal of molecular sciences· PUBMED
Trial
BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)
20 Jul 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
A Scalable Lentiviral Workflow for Laboratory-Scale Generation of BCMA/GPRC5D Co-Transduced CAR-T Cells in Multiple Myeloma.
30 Jun 2026· Current issues in molecular biology· PUBMED
Publication
Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.
27 Jun 2026· Clinical pharmacology and therapeutics· PUBMED
Trial
GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
25 Jun 2026· PHASE1 · RECRUITING· CTGOV
Publication
Correction: Efficacy and safety of BCMA-or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies.
22 Jun 2026· Frontiers in immunology· PUBMED
Trial
Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM)
1 Jun 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies.
20 May 2026· Frontiers in immunology· PUBMED
Publication
Forimtamig: a potent GPRC5D-targeted bispecific antibody in multiple myeloma.
20 Apr 2026· Annals of medicine and surgery (2012)· PUBMED
Publication
Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis.
31 Mar 2026· American journal of hematology· PUBMED
Publication
Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.
31 Mar 2026· Leukemia· PUBMED
Trial
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
26 Mar 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Publication
Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs.
5 Mar 2026· Blood· PUBMED
Trial
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
2 Mar 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Publication
Flat dose intravenous immunoglobulin primary infection prophylaxis in multiple myeloma patients on BCMA and GPRC5D bispecific antibody therapy: the Vanderbilt experience.
19 Feb 2026· Frontiers in immunology· PUBMED
Publication
YMN-V115: a novel humanized BCMA/GPRC5D/CD3 trispecific antibody in relapsed/refractory multiple myeloma.
18 Feb 2026· Journal for immunotherapy of cancer· PUBMED
Publication
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.
17 Feb 2026· Leukemia· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error